IP Library Granted Patent US 9,255,119
Granted Patent B2
US 9,255,119 · App. 14/256,235 · Granted Feb 9, 2016

Process for perparing fondaparinux sodium and intermediates useful in the synthesis thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,255,119
App. No.
14/256,235
Granted
Feb 9, 2016
Kind
B2
Abstract

Processes for the synthesis of the Factor Xa anticoagulent Fondaparinux, and related compounds are described. Also described are protected pentasaccharide intermediates as well as efficient and scalable processes for the industrial scale production of Fondaparinux sodium by conversion of the protected pentasaccharide intermediates via a sequence of deprotection and sulfonation reactions.

Claims (10)

1. A process for making a compound of Formula I

wherein R 1 is tetrahydropyran (THP), R 2 is —OSO 3 Na, R 3 is H, R 4 is NHSO 3 Na, R 5 is methyl, and R 6 and R 7 are —CO 2 Na,

the process comprising the step of sulfating a compound of

or a salt thereof.

2. A process for making a compound of Formula I:

wherein R 1 is H, R 2 is —OSO 3 Na, R 3 is H, R 4 is NHSO 3 Na, R 5 is methyl, and R 6 and R 7 are —CO 2 Na;

the process comprising deprotecting a compound of the formula:

3. A process for making a compound of Formula 8:

comprising reacting a compound of Formula 9:

with a compound of Formula 10:

Assignments (8)
TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENTS Recorded Nov 16, 2020
From: THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A.
To: AVANTOR PERFORMANCE MATERIALS, LLC; NUSIL TECHNOLOGY LLC; APPLIED SILICONE COMPANY LLC; RELIABLE BIOPHARMACEUTICAL, LLC; THERAPAK, LLC
Reel/Frame 054440/0877 →
SECURITY AGREEMENT (NOTES) Recorded Nov 6, 2020
From: AVANTOR FLUID HANDLING, LLC; AVANTOR PERFORMANCE MATERIALS, LLC; NUSIL TECHNOLOGY LLC; RELIABLE BIOPHARMACEUTICAL, LLC; THERAPAK, LLC
To: THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., AS NOTES COLLATERAL AGENT
Reel/Frame 054343/0414 →
SECURITY AGREEMENT Recorded Nov 29, 2017
From: AVANTOR PERFORMANCE MATERIALS, LLC; NUSIL TECHNOLOGY LLC; APPLIED SILICONE COMPANY LLC; RELIABLE BIOPHARMACEUTICAL, LLC; THERAPAK, LLC
To: THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., AS NOTES COLLATERAL AGENT
Reel/Frame 044528/0960 →
SECURITY AGREEMENT Recorded Nov 28, 2017
From: AVANTOR PERFORMANCE MATERIALS, LLC; NUSIL TECHNOLOGY LLC; APPLIED SILICONE COMPANY LLC; RELIABLE BIOPHARMACEUTICAL, LLC; THERAPAK, LLC
To: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
Reel/Frame 044811/0400 →
RELEASE (REEL 040913 / FRAME 0118) Recorded Nov 27, 2017
From: CITIBANK, N.A.
To: RELIABLE BIOPHARMACEUTICAL, LLC
Reel/Frame 044511/0265 →
SECURITY AGREEMENT Recorded Dec 14, 2016
From: RELIABLE BIOPHARMACEUTICAL, LLC
To: CITIBANK, N.A., AS COLLATERAL AGENT
Reel/Frame 040913/0118 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 10, 2016
From: RELIABLE BIOPHARMACEUTICAL CORPORATION
To: RELIABLE BIOPHARMACEUTICAL, LLC
Reel/Frame 040277/0548 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 31, 2016
From: RELIABLE BIOPHARMACEUTICAL CORPORATION
To: RELIABLE BIOPHARMACEUTICAL, LLC
Reel/Frame 040174/0564 →